Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Reports Q3 2026 Revenue of $3.44 Billion and Raises Guidance

Mixed Impact 4 of 5 earnings

Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, representing a 12% increase compared to the same period in 2025, driven by cystic fibrosis therapies and newer product growth. The company raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion following strong performance and the closing of the Crinetics Pharmaceuticals acquisition. GAAP net income declined year-over-year to $654 million due to acquisition-related expenses.

Key points

  • Total revenue for the third quarter of 2026 reached $3.44 billion, up 12% year-over-year.
  • Full-year 2026 revenue guidance was raised to a range of $13.15 billion to $13.25 billion.
  • GAAP net income was $654 million for the third quarter of 2026, compared to $1.1 billion in the third quarter of 2025.
  • The acquisition of Crinetics Pharmaceuticals closed on September 1, 2026.

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:05 PM ET
Accession number0000875320-26-000287

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 2, 2026, 4:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.